Endo International PLC (NASDAQ:ENDP) (TSE:ENL) has earned a consensus recommendation of “Hold” from the twenty-three brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $15.32.
A number of equities analysts have commented on the stock. TheStreet downgraded shares of Endo International from a “c-” rating to a “d+” rating in a report on Tuesday. Stifel Nicolaus boosted their target price on shares of Endo International from $10.00 to $17.00 and gave the stock a “hold” rating in a report on Thursday, August 9th. BMO Capital Markets boosted their target price on shares of Endo International from $9.00 to $16.00 and gave the stock a “market perform” rating in a report on Friday, August 10th. They noted that the move was a valuation call. Cantor Fitzgerald set a $12.00 target price on shares of Endo International and gave the stock a “hold” rating in a report on Wednesday, August 8th. Finally, Cowen reiterated a “hold” rating and issued a $9.00 target price on shares of Endo International in a report on Friday, November 9th.
In other news, Director Nancy J. Hutson sold 10,000 shares of the business’s stock in a transaction dated Thursday, November 15th. The stock was sold at an average price of $12.83, for a total transaction of $128,300.00. Following the sale, the director now owns 49,970 shares in the company, valued at $641,115.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.80% of the stock is currently owned by insiders.
Shares of ENDP stock traded down $0.12 on Monday, hitting $12.03. The stock had a trading volume of 2,760,847 shares, compared to its average volume of 4,463,323. The company has a market capitalization of $2.73 billion, a P/E ratio of 3.13, a PEG ratio of 4.45 and a beta of 0.65. Endo International has a one year low of $5.27 and a one year high of $18.50.
Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings data on Thursday, November 8th. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.12. The firm had revenue of $745.00 million during the quarter, compared to the consensus estimate of $694.93 million. Endo International had a positive return on equity of 1,348.52% and a negative net margin of 37.82%. The firm’s quarterly revenue was down 5.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.91 earnings per share. On average, analysts predict that Endo International will post 2.73 EPS for the current year.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Featured Story: What are the economic characteristics of a bear market?
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.